Indefinite Delivery Contract HHSN261201200032I

The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a multiple-award indefinite delivery/indefinite quantity (IDIQ) contract to Weill Medical College of Cornell University to provide preclinical research services for the PREVENT Cancer Preclinical Drug Development Program. Under this $149,995,000 IDIQ, the contractor performs efficacy testing, biomarker evaluation, and analytical assay development to advance cancer...

This indefinite delivery contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to the University of Alabama at Birmingham (UAB) to support the agency's Preclinical Prevent Cancer Program. The program focuses on evaluating the preclinical efficacy and identifying intermediate biomarkers for potential cancer prevention agents prior to clinical trials. Under this $29.8 million multiple-award IDC, UAB has been issued multiple...

The National Cancer Institute (NCI), part of the Department of Health and Human Services, has awarded an Indefinite Delivery Contract (IDC) valued at $29,800,000 to The Institute for Cancer Research, a non-profit subsidiary of Temple University. The contract, titled "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS," has a period of performance from September 22, 2015 to September 21, 2018. Under this multiple-award IDC, The Institute for...

This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and...

The contract IDV award is for the PREVENT Cancer Preclinical Drug Development Program, a multiple-award IDIQ contract administered by the National Cancer Institute (NCI). The program encompasses three main technical areas: (1) evaluation of the efficacy and pharmacodynamic/efficacy biomarkers for potential cancer preventive agents, (2) preclinical product development, analytical testing, process development, and cGMP manufacturing support for cancer preventive vaccines, and (3) pharmacological...

The University of Texas MD Anderson Cancer Center was awarded an indefinite delivery, indefinite quantity (IDIQ) contract from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to support the PREVENT Preclinical Drug Development Program. This multiple award IDIQ has a $74,995,000 ceiling and a 5-year base period with a 5-year option. It covers three pools of services: preclinical efficacy and biomarker evaluation, preclinical GMP product development and...

This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The contract, valued at up to $74,995,000, is a multiple award with Advanced Bioscience Laboratories, Inc. (ABL) as the prime contractor. The contract supports the PREVENT Cancer Preclinical Drug Development Program, with the objective of cGMP production of vaccines and biologicals for cancer prevention. Key...

The National Cancer Institute (NCI) awarded a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value to The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year IDC contract includes three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product...

This federal indefinite delivery contract was awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the non-profit IIT Research Institute (IITRI). The $19 million PREVENT Toxicology and Pharmacology Testing (PREVENT TOX) IDIQ contract vehicle enables NCI to efficiently access IITRI's preclinical research capabilities on an as-needed basis to support the development of cancer prevention therapies. Task orders issued under this...

This indefinite delivery contract (IDC) was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson). The $149,995,000 multiple-award IDIQ contract supports the NCI's "PREVENT Cancer Preclinical Drug Development Program" and covers preclinical efficacy and biomarker evaluation of potential cancer preventive agents. Under this IDC, MD Anderson has been awarded a $1,144,300...